Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hind Rafei

Showing results (41-50 of 53) with videos related to

Pageof 6
Sort By:
Science Advances|July 26, 2023
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineeringLi Li, Vakul Mohanty, Jinzhuang Dou, et al.
Nature Medicine|September 29, 2022
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escapeYe Li, Rafet Basar, Guohui Wang, et al.
Nature Medicine|January 5, 2024
Author Correction: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escapeYe Li, Rafet Basar, Guohui Wang, et al.
Nature Medicine|June 26, 2025
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialYago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al.
Nature Medicine|April 4, 2025
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialYago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al.
Cytotherapy|December 15, 2025
Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftmentPortia Smallbone, Mayela Mendt, Robert Sackstein, et al.
Cancer Cell|August 22, 2025
Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potencyAlexander Biederstädt, Rafet Basar, Jeong-Min Park, et al.
Cancer Cell|August 13, 2024
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPDMayra Shanley, May Daher, Jinzhuang Dou, et al.
Nature Medicine|January 18, 2024
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19<sup>+</sup> B cell tumors: a phase 1/2 trialDavid Marin, Ye Li, Rafet Basar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2021
Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following AllotransplantationAmanda Olson, Ruitao Lin, David Marin, et al.
Pageof 6

Showing results (41-50 of 53) with videos related to

Sort By:
Pageof 6
Science Advances|July 26, 2023
Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineeringLi Li, Vakul Mohanty, Jinzhuang Dou, et al.
Nature Medicine|September 29, 2022
KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escapeYe Li, Rafet Basar, Guohui Wang, et al.
Nature Medicine|January 5, 2024
Author Correction: KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escapeYe Li, Rafet Basar, Guohui Wang, et al.
Nature Medicine|June 26, 2025
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialYago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al.
Nature Medicine|April 4, 2025
Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trialYago Nieto, Pinaki Banerjee, Indreshpal Kaur, et al.
Cytotherapy|December 15, 2025
Ex vivo mesenchymal progenitor cell-based cord blood cell expansion and exofucosylation to enhance transplant engraftmentPortia Smallbone, Mayela Mendt, Robert Sackstein, et al.
Cancer Cell|August 22, 2025
Genome-wide CRISPR screens identify critical targets to enhance CAR-NK cell antitumor potencyAlexander Biederstädt, Rafet Basar, Jeong-Min Park, et al.
Cancer Cell|August 13, 2024
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPDMayra Shanley, May Daher, Jinzhuang Dou, et al.
Nature Medicine|January 18, 2024
Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19<sup>+</sup> B cell tumors: a phase 1/2 trialDavid Marin, Ye Li, Rafet Basar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 30, 2021
Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following AllotransplantationAmanda Olson, Ruitao Lin, David Marin, et al.
Pageof 6